4th Annual Live Medical Crossfire®: Hematologic Malignancies

Release Date: August 14, 2020
Expiration Date: August 14, 2021

Activity Overview

Current standards of practice in the treatment of hematologic malignancies are continually evolving as new clinical trial data emerge. Physicians who treat a broad range of patients with hematologic malignancies—leukemia, lymphoma, and myeloma—need to stay informed about current controversies and changing treatment paradigmsin these tumor types across multiple lines of care to confidently personalize clinical decisions for their patients. As such, comprehensive case-based discussions that provide real-world clinical perspectives can help shape modern management of hematologic malignancies today.

This Online! Medical Crossfire®: Hematologic Malignancies program provides presentations from the 4th Annual Live Medical Crossfire®: Hematologic Malignancies, held on July 11, 2020. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects managing patients with hematologic malignancies. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Support

This educational activity is supported by educational grants from AbbVie Inc.; AstraZeneca; Genmab US, Inc.; Incyte Corporation; Oncopeptides, Inc.; Pfizer Inc.; and Sanofi Genzyme.
 

Target Audience

This educational activity is directed toward hematologic and medical oncologists involved in the treatment and management of patients with hematologic malignancies, including leukemia, lymphoma, and multiple myeloma. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, investigators, and other healthcare professionals interested in the treatment of hematologic malignancies are also invited toparticipate.

Learning Objectives prepared to

Upon successful completion of this activity, you should be better prepared to:

• Analyze testing strategies that may inform clinical decision-making in the management of hematologic malignancies
• Apply clinical trial results to multiple lines of care in the management of hematologic malignancies
• Implement optimal strategies to treat hematologic malignancies
• Assess disparities in care for patients with hematologic malignancies
• Develop strategies to proactively prevent, minimize, and manage treatment-related toxicities in patients with leukemia, lymphoma, or multiple myeloma
• Discuss key emerging data sets regarding the management of patients with hematologic malignancies

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
 

Co-Chairs

Kenneth C. Anderson, MD
Program Director
Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics
Dana-Farber Cancer Institute
Institute Physician
Kraft Family Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures:Consultant: Bristol Myers Squibb, Celgene, Gilead, Janssen, Millennium Pharmaceuticals, Sanofi; Shareholder: Scientific founder: OncoPep/C4 Therapeutics.

Elias Jabbour, MD
Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures:Grant/Research Support: AbbVie Inc, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Novartis, Pfizer, Spectrum Pharmaceuticals, Takeda Pharmaceutical Company.

Faculty

Anjali Advani, MD
Director, Inpatient Leukemia Program
Taussig Cancer Institute
Professor, Cleveland Clinic Lerner College of Medicine
Cleveland Clinic
Cleveland, OH

Disclosures:Grant/Research Support: AbbVie Inc, Amgen, GlycoMimetics, MacroGenics, Pfizer; Consultant: Kite Pharma, Seattle Genetics; Other: Honoraria: Pfizer; Steering committee: Amgen.

Ajai Chari, MD
Professor of Medicine, Hematology, and Medical Oncology
Icahn School of Medicine at Mount Sinai
New York, NY

Disclosures:Grant/Research Support: Amgen, Celgene, Janssen, Novartis, Pharmacyclics, Seattle Genetics, Takeda Pharmaceutical Company; Consultant: Amgen, Antengene Corporation, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Novartis, Oncopeptides, Sanofi, Seattle Genetics, Secura Bio, Takeda Pharmaceutical Company.

Jorge E. Cortes, MD
Director, Georgia Cancer Center
Eminent Scholar, Georgia Research Alliance
Augusta University
Augusta, GA

Disclosures:Grant/Research Support: Bristol Myers Squibb, Novartis, Pfizer, Sun Pharmaceutical Industries, Takeda Pharmaceutical Company; Consultant: Bristol Myers Squibb, Novartis, Pfizer, Takeda Pharmaceutical Company.

Naval G. Daver, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures:Grant/Research Support: AbbVie Inc, Astellas Pharma, Bristol Myers Squibb, Daiichi Sankyo, Forty Seven, Genentech, Gilead Sciences, ImmunoGen, Incyte Corporation, Jazz Pharmaceuticals, Novartis, Novimmune, Otsuka Pharmaceutical, Pfizer, Roche, Trillium Therapeutics; Consultant: AbbVie Inc, Astellas Pharma, Bristol Myers Squibb, Daiichi Sankyo, Forty Seven, Genentech, Gilead Sciences, ImmunoGen, Incyte Corporation, Jazz Pharmaceuticals, Novartis, Otsuka Pharmaceutical, Pfizer, Roche, Trillium Therapeutics.

Faith Davies, MBBCh, MRCP, MD, FRCPath
Professor of Medicine
Director of Clinical Myeloma Program
Perlmutter Cancer Center
NYU Langone Health
New York, NY

Disclosures:Grant/Research Support: Celgene; Consultant: Adaptive Biotechnologies, Bristol Myers Squibb, Celgene, Janssen, Roche, Sanofi, Takeda Pharmaceutical Company.

Amir T. Fathi, MD
Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures:Grant/Research Support: Agios Pharmaceuticals, Celgene, Seattle Genetics; Consultant: AbbVie Inc, Agios Pharmaceuticals, Amgen, Astellas Pharma, Celgene (Bristol Myers Squibb), Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Takeda Pharmaceutical Company; Other: Advisory board participant for Agios Pharmaceuticals, Amgen, Celgene (Bristol Myers Squibb), Seattle Genetics.

Nitin Jain, MD
Associate Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures:Grant/Research Support: AbbVie Inc, ADC Therapeutics, Bristol Myers Squibb, Celgene, Genentech, Incyte Corporation, Infinity Pharmaceuticals, Pfizer, Pharmacyclics, Seattle Genetics, Servier Pharmaceuticals; Consultant: Adaptive Biotechnologies, ADC Therapeutics, Novartis, Novimmune, Pfizer, Pharmacyclics, Servier Pharmaceuticals.

Suzanne Lentzsch, MD, PhD
Professor of Clinical Medicine
Columbia University
Director, Multiple Myeloma and Amyloidosis Service
Columbia University Irving Medical Center
New York, NY

Disclosures:Grant/Research Support: Karyopharm Therapeutics, Sanofi; Consultant: AbbVie Inc, Amgen, Caelum BioScience, Janssen Pharmaceuticals, Sanofi, Sorrento Therapeutics; Shareholder: Caelum BioSciences; Other: Board of Directors: Caelum BioSciences.

John P. Leonard, MD
Senior Associate Dean for Innovation and Initiatives
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Weill Cornell Medicine and NewYork-Presbyterian Hospital
New York, NY

Disclosures:Consultant: ADC Therapeutics, AstraZeneca, Bayer, Bristol Myers Squibb/Celgene, Epizyme, Genmab, Gilead/Kite, Karyopharm Therapeutics, MEI Pharma, Miltenyi Biotec, Regeneron Pharmaceuticals, Sutro Biopharma.

Lori Leslie, MD
Lead, Indolent Lymphoma Research Program
Lymphoma Division
John Theurer Cancer Center/Hackensack Meridian Health
Hackensack, NJ

Disclosures:Consultant: AbbVie Inc, ADC Therapeutics, AstraZeneca, Bayer, Celgene/Bristol Myers Squibb, Genentech, Janssen Pharmaceuticals, Kite Pharma, Pharmacyclics, Seattle Genetics; Speakers Bureau: AstraZeneca, BeiGene, Celgene/Bristol Myers Squibb, Kite Pharma, Pharmacyclics/Janssen, Seattle Genetics.

Aaron Logan, MD, PhD
Associate Professor of Clinical Medicine, Division of Hematology/Oncology
University of California San Francisco
San Francisco, CA

Disclosures:Grant/Research Support: Astellas Pharma, Jazz Pharmaceuticals, Kite Pharma, Pharmacyclics; Consultant: Amgen, Incyte Corporation, Pfizer.

Selina Luger, MD
Professor of Medicine
Abramson Cancer Center
Perelman School of Medicine, University of Pennsylvania
Philadelphia, PA

Disclosures:Grant/Research Support: BioSight, Celgene, F. Hoffmann-La Roche, Kura Oncology, Onconova Therapeutics; Other: Honoraria: Acceleron Pharma, Agios Pharmaceuticals, Daiichi Sankyo, Bristol Myers Squibb, Jazz Pharmaceuticals.

Kami J. Maddocks, MD
Associate Professor of Clinical Internal Medicine
Lymphoma Program Director
Division of Hematology, Department of Internal Medicine
The Arthur G. James Cancer Hospital at The Ohio State University
Columbus, OH

Disclosures:Consultant: Celgene, MorphoSys, Pharmacyclics, Karyopharm Therapeutics.

Peter Martin, MD
Associate Professor of Medicine
Weill Cornell Medicine
New York, NY

Disclosures:Consultant: Bayer, BeiGene, Celgene, Cellectar Biosciences, Karyopharm Therapeutics, Kite Pharma, I-Mab, Janssen Pharmaceuticals, MorphoSys, Regeneron Pharmaceuticals, Sandoz.

Anthony Mato, MD, MSCE
Director, CLL Program
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures:Grant/Research Support: AbbVie Inc, Acerta/AstraZeneca, Adaptive Biotechnologies, DTRM, Loxo, Pharmacyclics, Regeneron, Sunesis Pharmaceuticals, TG Therapeutics; Consultant: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Celgene, Johnson & Johnson, Loxo Oncology, Pharmacyclics, Regeneron Pharmaceuticals, Sunesis Pharmaceuticals, TG Therapeutics; Other: TG Therapeutics/Celgene (data and safety monitoring board).

Michael J. Mauro, MD
Leader, Myeloproliferative Neoplasms Program
Attending Physician, Leukemia Service
Member, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College
New York, NY

Disclosures:Consultant: ARIAD Pharmaceuticals, Bristol Myers Squibb, Novartis Oncology, Pfizer.

Javier Pinilla-Ibarz, MD, PhD
Senior Member
Head, Lymphoma Section
Director of Immunotherapy
Department of Malignant Hematology
Moffitt Cancer Center
Tampa, FL

Disclosures:Consultant: AbbVie Inc, Gilead Sciences, Janssen Pharmaceuticals, Novartis, Pfizer, Pharmacyclics; Speakers Bureau: AbbVie Inc, Gilead Sciences, Pharmacyclics, Takeda Pharmaceutical Company.

Jerald P. Radich, MD
Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Professor, Division of Medical Oncology
University of Washington School of Medicine
Seattle, WA

Disclosures:Grant/Research Support: Novartis; Consultant: Amgen, Bristol Myers Squibb, Cepheid, Genentech, Novartis, Takeda Pharmaceutical Company.

Noopur Raje, MD
Professor of Medicine
Harvard Medical School
Director, Multiple Myeloma Center
Massachusetts General Hospital
Boston, MA

Disclosures:Grant/Research Support: bluebird bio; Consultant: Amgen, Bristol Myers Squibb, Caribou Biosciences, Celgene, Immuneel Therapeutics, Karyopharm Therapeutics, Takeda.

Gilles A. Salles, MD, PhD
University Professor
Head of Hematology
Claude Bernard University of Lyon
Hospices Civils de Lyon
Lyon, France

Disclosures:Consultant: AbbVie Inc, Amgen, Autolus Therapeutics, Celgene, Epizyme, Gilead Sciences, Janssen Pharmaceuticals, Kite Pharma, MorphoSys, Novartis, Roche, Servier Pharmaceuticals, Takeda Pharmaceutical Company.

Stephen J. Schuster, MD
Director, Lymphoma Program and Lymphoma Translational Research
Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma
Abramson Cancer Center, University of Pennsylvania
Philadelphia, PA

Disclosures:Grant/Research Support: AbbVie Inc, Acerta Pharma, Celgene, Genentech/Roche, Juno Therapeutics, Merck & Co, Novartis; Consultant: Acerta Pharma, Allogene Therapeutics, AstraZeneca, BeiGene, Celgene, Genentech/Roche, Juno Therapeutics, Loxo Oncology, Nordic Nanovector, Novartis, Tessa Therapeutics.

Bijal D. Shah, MD, MS
Associate Professor, Malignant Hematology
Moffitt Cancer Center
Tampa, FL

Disclosures:Grant/Research Support: Incyte Corporation, Jazz Pharmaceuticals, Kite/Gilead, Servier Pharmaceuticals; Consultant: Adaptive, Amgen, AstraZeneca, BeiGene, Celgene/BMS, Kite/Gilead, Novartis, Pfizer, Pharmacyclics/Janssen, Precision Biosciences, Spectrum/Acrotech.

Mitchell R. Smith, MD, PhD
Associate Center Director for Clinical Investigations
Director, Division of Hematology and Oncology
The George Washington University Cancer Center
Washington, DC

Disclosures:Consultant: AstraZeneca, Celgene, Genentech; Speakers Bureau: AstraZeneca.

Wendy Stock, MD
Anjuli Seth Nayak Professor in Leukemia
Director, Leukemia Program
Section of Hematology/Oncology
The University of Chicago
Chicago, IL

Disclosures:Consultant: AbbVie Inc, Agios Pharmaceuticals, Amgen, Astellas Pharma, Daiichi Sankyo, Kite Pharma, MorphoSys, Pfizer, Servier Pharmaceuticals; Speakers Bureau: AbbVie Inc.

Richard M. Stone, MD
Professor of Medicine, Harvard Medical School
Chief of Staff
Director, Adult Leukemia Program
Dana-Farber Cancer Institute
Boston, MA

Disclosures:Grant/Research Support: Agios Pharmaceuticals, Arog Pharmaceuticals, Novartis; Consultant: AbbVie Inc, Agios Pharmaceuticals, Amgen, Arog Pharmaceuticals, AstraZeneca, Astellas Pharma, Celgene, Cornerstone Pharmaceuticals, Fujifilm, Janssen, Jazz Pharmaceuticals, Juno Therapeutics, MacroGenics, Novartis, Ono Pharmaceutical Co, Orsenix, Otsuka/Astex, Pfizer, Sumitomo; Other: Argenx, Celgene, Takeda Pharmaceutical Company, (data and safety monitoring board); Actinium Pharmaceuticals (scientific advisory board).

Jason Westin, MD, MS, FACP
Director, Lymphoma Clinical Research Program
Section Chief, Aggressive Lymphoma
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures:Grant/Research Support: AstraZeneca, Bristol Myers Squibb, Curis, Genentech, Jenssen, Kite, Morphosys, Novartis, Unum; Consultant: AstraZeneca, Bristol Myers Squibb, Curis, Genentech, Jenssen, Kite, Morphosys, Novartis.

Adrian Wiestner, MD, PhD
Senior Investigator
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, MD

Disclosures:Grant/Research Support: Acerta Pharma, Genmab, Merck & Co, Nurix Therapeutics, Pharmacyclics, Verastem Oncology; Consultant: Pharmacyclics.

Jennifer A. Woyach, MD
Associate Professor
Division of Hematology
Department of Internal Medicine
The Ohio State University
Columbus, OH

Disclosures:Grant/Research Support: AbbVie Inc, Loxo Oncology, Janssen Pharmaceuticals, Pharmacyclics, Karyopharm Therapeutics, MorphoSys, Verastem Oncology; Consultant: ArQule, AstraZeneca, Janssen Pharmaceuticals, Pharmacyclics.

The staff Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.